Drugs / DIAZEPINOMICIN
DIAZEPINOMICIN
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00338026 | Feb 2006 → Aug 2007 | breast cancer, colorectal cancer, glioma, lung cancer +3 | Thallion Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03493607 | May 2018 → Mar 2020 | Phelan-McDermid syndrome, epilepsy | Alexander Kolevzon | Completed | No outcome recorded |
| Phase 2 | NCT00730262 | Aug 2008 → Apr 2010 | glioblastoma | Thallion Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DIAZEPINOMICIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL550961 ↗ |
| Known as | AMO-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03493607 ↗ |
| Known as | BU-4664L | ChEMBL registry synonym — accepted as the source's own label CHEMBL550961 ↗ |
| Known as | ECO-4601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00338026 ↗ |
| Known as | TLN-4601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00730262 ↗ |
| Modality | Small molecule | — CHEMBL550961 ↗ |
| Route | Intravenous | “Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)” NCT00338026 ↗ |